A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Public ClinicalTrials.gov record NCT06760819. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations
Study identification
- NCT ID
- NCT06760819
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Interventions
- BAY2927088 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 12, 2025
- Primary completion
- Feb 2, 2027
- Completion
- Oct 24, 2027
- Last update posted
- May 6, 2026
2025 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital | Birmingham | Alabama | 35233 | Recruiting |
| City of Hope - Duarte Cancer Center | Duarte | California | 91010 | Recruiting |
| Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus | Fort Myers | Florida | 33908 | Recruiting |
| Dana-Farber Cancer Institute - Oncology Department | Boston | Massachusetts | 02215 | Recruiting |
| Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit | Detroit | Michigan | 48202 | Withdrawn |
| Profound Research -OMG - TriAtria Cancer Center | Farmington Hills | Michigan | 48334 | Recruiting |
| Cleveland Clinic - Oncology Department | Cleveland | Ohio | 44195 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| The University of Texas MD Anderson Cancer Center - Texas Medical Center | Houston | Texas | 77030 | Recruiting |
| Gynecology Oncology clinic at UW Medical Center - Montlake | Seattle | Washington | 98195 | Withdrawn |
| UW Health Carbone Cancer Center | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06760819, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06760819 live on ClinicalTrials.gov.